Latest Matuzumab Stories
CALGARY, July 6, 2011 /PRNewswire/ - Oncolytics Biotech Inc.
EXTON, Pa., June 28, 2011 /PRNewswire/ -- MorphotekÂ®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center phase II study of farletuzumab in adenocarcinoma of the lung, a type of non-small cell lung cancer (NSCLC).
CALGARY, June 8, 2011 /PRNewswire/ - Oncolytics Biotech Inc.
MISSISSAUGA, ON, Jan. 20 /PRNewswire/ - YM BioSciences Inc.
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.